2',6'-dichloro-2,3-dihydroxybiphenyl

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2',6'-dichloro-2,3-dihydroxybiphenyl
• 英文别名: 2',6'-dichlorobiphenyl-2,3-diol；2',6'-Dichloro-biphenyl-2,6-diol；3-(2,6-dichlorophenyl)benzene-1,2-diol
• 化学式: C₁₂H₈Cl₂O₂
• 分子量: 255.1
• InChiKey: MCZUCSAAGDCHHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,3-二甲氧基苯硼酸 在 四(三苯基膦)钯 三溴化硼 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 二氯甲烷 为溶剂， 反应 12.0h， 生成 2',6'-dichloro-2,3-dihydroxybiphenyl
  参考文献：
  名称：

  Combined Directed ortho Metalation/Suzuki−Miyaura Cross-Coupling Strategies. Regiospecific Synthesis of Chlorodihydroxybiphenyls and Polychlorinated Biphenyls

  摘要：

  The Directed ortho Metalation (DoM)/Suzuki-Miyaura cross-coupling strategy is applied for the regiospecific construction of all isomeric monochloro and selected dichloro and trichloro 2,3-dihydroxybiphenyls (DHBs). The combined methodology highlights iterative DoM processes, hindered Suzuki-Miyaura couplings, and advantages in diversity in approaches from commercial starting materials leading to provision of chloro-DHBs as single isomers in high purity and on a gram scale. The syntheis of several PCBs are also reported.

  DOI：

  10.1021/jo062543i

文献信息

• Benzodioxane and benzodioxolane derivatives and uses thereof
  申请人：Zhou Dahui

  公开号：US20060241172A1

  公开（公告）日：2006-10-26

  Compounds of formula I or pharmaceutically acceptable salts thereof are provided: wherein each of R 1 , R 2 , R 3 , R 4 , y, n, m, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.

  提供了化学式I或其药用可接受盐的化合物：其中R1、R2、R3、R4、y、n、m和Ar中的每一个如所定义，并在此处描述的类和亚类中，它们是大脑5-羟色胺受体2C亚型的激动剂或部分激动剂。这些化合物和含有这些化合物的组合物可用于治疗多种中枢神经系统疾病，如精神分裂症。
• METHODS AND AGENTS FOR TREATING TUBERCULOSIS
  申请人：Eltis Lindsay D.

  公开号：US20100041631A1

  公开（公告）日：2010-02-18

  The present invention relates to the treatment of tuberculosis (mycobacterial infections) by the use of KshAB complex inhibitors, or a KstD molecule, or a HsaAB complex, or a HsaC molecule, or a HsaD molecule. The application also includes a method for identifying an inhibitor or modulator of the previously mentioned molecules and complexes.

  本发明涉及使用KshAB复合物抑制剂、KstD分子、HsaAB复合物、HsaC分子或HsaD分子治疗结核病（分枝杆菌感染）。该申请还包括一种鉴定前述分子和复合物的抑制剂或调节剂的方法。
• BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF
  申请人：Wyeth

  公开号：EP1871759A1

  公开（公告）日：2008-01-02
• [EN] BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF<br/>[FR] DERIVES BENZODIOXANNE ET BENZODIOXOLANNE ET LEURS UTILISATIONS
  申请人：WYETH CORP

  公开号：WO2006116158A1

  公开（公告）日：2006-11-02

  [EN] Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided, wherein each of R¹, R², R³, R⁴, y, n, m, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.
  [FR] L'invention fournit des composés répondant à la formule (I) ou leurs sels acceptables sur le plan pharmaceutique, où R¹, R², R³, R⁴, y, n, m, et Ar sont chacun tels que définis, et décrits ici sous forme de classes et de sous-classes, lesquels sont des agonistes ou des agonistes partiels d'un sous-type 2C des récepteurs de la sérotonine dans le cerveau. Les composés, et les compositions contenant les composés, peuvent être utilisés pour traiter une variété de maladies du système nerveux central telles que la schizophrénie.
• [EN] METHODS AND AGENTS FOR TREATING TUBERCULOSIS<br/>[FR] MÉTHODES ET AGENTS DESTINÉS À TRAITER LA TUBERCULOSE
  申请人：UNIV BRITISH COLUMBIA

  公开号：WO2007118329A1

  公开（公告）日：2007-10-25

  [EN] The present invention relates to the treatment of tuberculosis (mycobacterial infections) by the use of KshAB complex inhibitors, or a KstD molecule, or a HsaAB complex, or a HsaC molecule, or a HsaD molecule. The application also includes a method for identifying an inhibitor or modulator of the previously mentioned molecules and complexes.
  [FR] L'invention concerne le traitement de la tuberculose (infections mycobactériennes) à l'aide d'inhibiteurs d'un complexe KshAB, ou d'une molécule KstD, ou d'un complexe HsaAB, ou d'une molécule HsaC, ou d'une molécule HsaD. La présente invention concerne en outre une méthode permettant d'identifier un inhibiteur ou un modulateur des molécules et complexes susmentionnés.